Placental Pathology and Inflammatory Factor Analysis of OAPS

Antiphospholipid Syndrome in Pregnancy Clinical Trial

Official title:
Placental Pathology and Inflammatory Factor Analysis of Obstetric Antiphospholipid Syndrome Patients

Status Recruiting

Clinical Trial Summary

This investigation is on placental pathological changes and inflammatory factors associated with obstetric antiphospholipid syndrome.

Clinical Trial Description

1. To clarify the correlation between antiphospholipid antibody, ACC1 expression level, Treg cell and placental pathological changes associated with antiphospholipid syndrome. 2. Reveal that antiphospholipid antibodies affect Treg cell differentiation through the key enzyme of lipid metabolism ACC1. ;

Study Design

Related Conditions & MeSH terms

Antiphospholipid Syndrome
Antiphospholipid Syndrome in Pregnancy
Syndrome

Clinical Trial Details

NCT number	NCT05378516
Study type	Observational
Source	Peking University People's Hospital
Contact	Jingjing Yang, deputy chief physician, doctor
Phone	0086-13810625484
Email	yjjbear2013@126.com
Status	Recruiting
Phase
Start date	January 1, 2022
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03100123` - AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study	Early Phase 1
Recruiting	`NCT03152058` - IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy	Phase 2
Recruiting	`NCT04275778` - HYDROxychloroquine in Syndrome Primary AntiPhospholipid	Phase 2
Recruiting	`NCT05679206` - Antiphospholipid Syndrome and Postpartum Pulmonary Artery Pressure
Recruiting	`NCT03505840` - The Value of Placental Vascularization and Placental Volume in Pregnancy in APLS
Withdrawn	`NCT04274803` - Dose Intralipid Infusion Reduces Pregnancy Complications Caused by Antiphospholipid Antibody Syndrome?	Phase 4